4.7 Article

Urinary 8-hydroxydeoxyguano sine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers

期刊

CLINICA CHIMICA ACTA
卷 334, 期 1-2, 页码 87-94

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/S0009-8981(03)00191-8

关键词

8-hydroxyguanine; competitive ELISA; oxidative stress; bladder cancer; prostate cancer

向作者/读者索取更多资源

Background: 8-hydroxydeoxyguanosine (8-OHdG) is the most frequently detected and studied DNA lesion. Upon DNA repair. 8-OHdG is excreted in the urine. Urinary 8-OHdG is now considered as a biomarker of generalized, cellular oxidative stress and is linked to degenerative diseases including cancer. Methods: We developed a competitive enzyme-linked immunosorbent assay (ELISA) for urinary 8-OHdG by coating BSA conjugated 8-hydroxyguanine (8-OHG) on a microplate. Urine specimens containing 8-OHdG and monoclonal anti-8-OHdG antibody were incubated together in the microwell. Final quantification of bound anti-8-OHdG antibody was estimated by the addition of HRP-conjugated sheep-anti-mouse antibody. Results: The concentration range of the calibration curve was 0-60 ng/ml. The sensitivity of the assay was 0.5 ng/ml. The within-day precision and day-to-day precision were < 10%. The ELISA correlated well with a commercial kit (r=0.9). Our assay measured not only 8-OHdG but also 8-OHG and 8-hyroxyguanine in urine. Increased urinary concentration of 8-OHdG and its analogs were detected in both patients with bladder cancer (70.5 +/- 38.2 ng/mg creatinine) and prostate cancer (58.8 +/- 43.4 ng/mg creatinine) as compared to the healthy control (36.1 +/- 24.5 ng/mg creatinine). Conclusion: Our preliminary data suggest that the competitive ELISA for 8-OHdG and its analogs appears to be a simple method for quantifying the extent of oxidative stress and may have potential for identifying cancer risk. (C) 2003 Elsevier Science B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据